Technology
Health
Biotechnology
Chimerix
$2.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Chimerix and other stocks, options, ETFs, and crypto commission-free!
About
Chimerix, Inc. Common Stock, also called Chimerix, is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Read More Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Employees
59
Headquarters
Durham, North Carolina
Founded
2000
Market Cap
101.47M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
244.77K
High Today
$2.02
Low Today
$1.92
Open Price
$2.00
Volume
307.06K
52 Week High
$5.48
52 Week Low
$1.74
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2013 IPO
US
North America
News
Simply Wall StMar 7
Some Chimerix Shareholders Have Taken A Painful 93% Share Price Drop
Long term investing works well, but it doesn’t always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Chimerix, Inc. (NASDAQ:CMRX) for five years would be nursing their metaphorical wounds since the share price dropped 93% in that time. And it’s not just long term holders hurting, because the stock is down 66% in the last year. Shareholders have had an even rougher run lately, with the share price down 43% in the last 90 days. This could be r...
MarketBeatFeb 24
Stock Price, News, & Analysis for Chimerix
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a ...
Price Paid on Robinhood
42% Lower
Right Now
52 Week Low
$1.74
Average Price Paid
$3.43
52 Week High
$5.48
Earnings
-$0.47
-$0.41
-$0.35
-$0.29
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, Pre-Market